Blue Water Vaccines (BWV) Reports Q1 Net Loss of $2.1M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments
May 13, 2022 5:01 PM EDTClosed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate developments, including additional data for universal influenza candidate, BWV-101, identifying additional epitopes of limited variability for H3N2 and influenza B strains$18.6 million in Cash as of March 31, 2022
CINCINNATI, May 13, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (BWV or Blue Water Vaccines or the Company), today announced its financial results for the first quarter ended March 31, 2022 and provided... More
